, Tracking Stock Market Picks
Enter Symbol:
Sunesis Pharmaceuticals, Inc. (SNSS) [hlAlert]

down 75.74 %

Sunesis Pharmaceuticals, Inc. (SNSS) rated Outperform by Wells Fargo

Posted on: Thursday,  Dec 20, 2012  8:25 AM ET by Wells Fargo

Wells Fargo rated Outperform Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) on 12/20/2012, when the stock price was $4.37. Since
then, Sunesis Pharmaceuticals, Inc. has lost 75.74% as of 01/08/2016's recent price of $1.06.
If you would have followed this Wells Fargo's recommendation on SNSS, you would have lost 75.74% of your investment in 1114 days.

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.

The investment research content is provided by Wells Capital Management, a registered investment adviser and wholly owned subsidiary of Wells Fargo Bank, N.A. Our economists’ expertise on domestic markets, and national and global trends, is an important resource to the firm. Wells Capital Management economists are known for their thoughts on investment strategy, macro-economic forecasts and other top-down analysis, and share their views on bonds, midcaps and liquidity management in their publications.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/20/2012 8:25 AM Buy
as of 12/31/2012
1 Week up  1.94 %
1 Month down  -3.89 %
3 Months   
1 YTD down  -3.89 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy